Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 4/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18182635 | 0.89 | HTT (0.61) | HTTTAS1R3TAS1R1TAS1R2RECQL | |
| SCHEMBL15355927 | 0.80 | HTT (0.47) | HTTTAS1R3TAS1R1TAS1R2RECQL | |
| SCHEMBL15984820 | 0.79 | RECQL (0.50) | HTTTAS1R3TAS1R1TAS1R2RECQL | |
| SCHEMBL13544870 | 0.78 | HTT (0.48) | HTTTAS1R3TAS1R1TAS1R2RECQL | |
| SCHEMBL13544601 | 0.78 | HTT (0.48) | HTTTAS1R3TAS1R1TAS1R2RECQL | |
| SCHEMBL13791344 | 0.77 | RECQL (0.45) | HTTTAS1R3TAS1R1TAS1R2RECQL | |
| SCHEMBL14506083 | 0.76 | HTT (0.43) | HTTTAS1R3TAS1R1TAS1R2RECQL | |
| SCHEMBL15355928 | 0.73 | RECQL (0.41) | HTTTAS1R3TAS1R1TAS1R2RECQL | |
| SCHEMBL13791949 | 0.73 | RECQL (0.41) | HTTTAS1R3TAS1R1TAS1R2RECQL | |
| SCHEMBL8526114 | 0.72 | HTT (0.69) | HTTTAS1R3TAS1R1TAS1R2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655236-B2 | Activity-based probe compounds, compositions, and methods of use | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-05-23 | — | — | US | disclosed |
| US-20160039792-A1 | ACTIVITY-BASED PROBE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-02-11 | — | — | US | disclosed |
| US-20100166706-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-7671032-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2010-01-07 | — | — | US | disclosed |
| US-7608590-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2009-10-27 | — | — | US | disclosed |
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2007-08-30 | — | — | US | disclosed |
| US-7247728-B2 | Bicyclic N-arylamides | BAYER HEALTHCARE AG (DE) | 2007-07-24 | — | — | US | disclosed |
| US-7247728-B2 | Bicyclic N-arylamides | BAYER HEALTHCARE AG (DE) | 2007-07-24 | — | — | US | disclosed |
| US-20070161574-A1 | Hcv ns-3 serine protease inhibitors | MEDIVIR AB (SE) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | SPINT2, SF3A3, GTF3C3 | HTT 3491/4885TAS1R3 2390/4885TAS1R1 3908/4885 |
| US-20100166706-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | HPN, CPN1, PRSS1 | HTT 4251/4885TAS1R3 3255/4885TAS1R1 4102/4885 |
| US-20070161574-A1 | Hcv ns-3 serine protease inhibitors | PRSS1, HPN, SPINT2 | HTT 4153/4885TAS1R3 2789/4885TAS1R1 3915/4885 |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | HPN, CPN1, PRSS1 | HTT 3795/4885TAS1R3 2997/4885TAS1R1 3980/4885 |
| US-11655236-B2 | Activity-based probe compounds, compositions, and methods of use | DNPEP, CTSF, CTSE | HTT 2554/4885TAS1R3 4376/4885TAS1R1 4326/4885 |
| US-20160039792-A1 | ACTIVITY-BASED PROBE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | DNPEP, CTSF, CTSE | HTT 2554/4885TAS1R3 4376/4885TAS1R1 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.